Skip to main content
. Author manuscript; available in PMC: 2020 May 4.
Published in final edited form as: Nat Rev Clin Oncol. 2019 Feb;16(2):73–74. doi: 10.1038/s41571-018-0156-2

Fig. 1 |. Developments in the treatment of AML.

Fig. 1 |

AML, acute myeloid leukaemia; CR, complete remission; CRc, composite complete remission; CRh, CR with incomplete haematological recovery; CRi, complete remission with incomplete neutrophil or platelet recovery; EFS, event-free survival; HMA, hypomethylating agent; ITD, internal tandem duplication; MDS, myelodysplastic syndrome; OS, overall survival; ORR, overall response rate; R/R, relapsed and/or refractory.